Literature DB >> 16264206

Coronary artery perforation during percutaneous coronary intervention: incidence and outcomes in the new interventional era.

Ravi K Ramana1, Dinesh Arab, Dominique Joyal, Lowell Steen, Leslie Cho, Bruce Lewis, Jayson Liu, Henry Loeb, Ferdinand Leya.   

Abstract

BACKGROUND: Coronary artery perforation (CP) is a serious complication of percutaneous coronary intervention (PCI). We sought to define the incidence and outcome of CP given the advance in interventional techniques, devices and use of glycoprotein inhibitors (GP IIb/IIIa).
METHODS: We retrospectively reviewed the records of patients who underwent PCI at our institution over a four-year period. The incidence of CP was derived from patient records and then confirmed by reviewing the angiogram. Perforations were classified as Type 1, 2, or 3, as previously defined.
RESULTS: A total of 4,886 patients underwent PCI. Atherectomy devices were used in 329 patients and GP IIb/IIIa in 2,200 patients. Twenty-five CP were identified (0.5% incidence). Six were Type 1 (24%), 10 were Type 2 (40%), and 9 were Type 3 (36%). 13/25 (52%) of the CP were Type C Lesions, and 12/25 (48%) occurred in calcified vessels. All Type 1 perforations were caused by coronary wires and 4/6 CP occurred with the use of hydrophilic and extra stiff wires. Type 2 perforations were caused by coronary wires in 8/10 CP, and by stent deployment in 2/10. Two patients with Type 2 CP sustained a non-ST-elevation myocardial infarction. Type 3 perforations were caused by stent placement in 4/9 CP, 2/9 by atherectomy devices, and 3/9 by coronary wires. Four patients with Type 3 CP underwent pericardial drainage, 5 patients had a myocardial infarction and 2 patients died.
CONCLUSION: Type 1 and 2 perforations are predominately caused by hydrophilic and stiff wires and do not require pericardial drainage or surgical intervention. Type 3 perforations are more often associated with stent and device use. A majority of Type 3 perforations can be initially managed by percutaneous methods.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264206

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  7 in total

1.  Is a metallic microcoil really a permanent embolic agent for the management of distal guidewire-induced coronary artery perforation?

Authors:  Jae Hyun Kim; Min-Kyu Kim; Young Jin Kim; Sun Man Park; Kyoung-Ha Park; Young-Jin Choi
Journal:  Korean Circ J       Date:  2011-08-31       Impact factor: 3.243

2.  Coronary perforation and covered stents: an update and review.

Authors:  Mohammed Al-Mukhaini; Prashanth Panduranga; Kadhim Sulaiman; Abdulla Amour Riyami; Mohammed Deeb; Mohamed Barkat Riyami
Journal:  Heart Views       Date:  2011-04

3.  Fatal delayed coronary artery perforation after coronary stent implantation.

Authors:  Sang-Hoon Kim; Jae-Youn Moon; Jung-Hoon Sung; In Jai Kim; Sang-Wook Lim; Dong-Hun Cha; Seung-Yun Cho
Journal:  Korean Circ J       Date:  2012-05-24       Impact factor: 3.243

4.  Rare occurrence of simultaneous coronary artery perforation and intracoronary thrombus formation following angioplasty.

Authors:  Su-Yan Bian; Liu-Fa Duan
Journal:  J Geriatr Cardiol       Date:  2013-06       Impact factor: 3.327

5.  Successful management of coronary artery rupture with stent-graft: a case report.

Authors:  Berkay Ekici; Aycan Fahri Erkan; Utku Kütük; Hasan Fehmi Töre
Journal:  Case Rep Med       Date:  2014-07-13

6.  Spontaneous closure of an iatrogenic coronary artery fistula during recanalization of a chronic total occlusion lesion: A case report.

Authors:  Xue Yu; Xinyue Wang; Ruisheng Zhang; Feng Xu; Fusui Ji
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

7.  Pseudo cardiac tamponade in the setting of excess pericardial fat.

Authors:  Thang Nguyen; Kanwal Kumar; Andrew Francis; Jonathan R Walker; Michael Raabe; Shelley Zieroth; Davinder S Jassal
Journal:  Cardiovasc Ultrasound       Date:  2009-01-22       Impact factor: 2.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.